The psychedelic renaissance has already been catalysed by a number of Breakthrough Therapy Designations from the U.S. FDA. Now, other national regulators are demonstrating interest in accelerating psychedelic drug development, with a fresh programme in post-Brexit UK representing a new ‘fast-track’ route. This week we learned that London-based Small Pharma is the first psychedelics company (to our…
